Phase 3 Randomized, Double-Blind, Multi-Dose, Placebo And NSAID Controlled Study To Evaluate The Efficacy And Safety Of Fasinumab In Patients With Pain Due To Osteoarthritis Of The Knee Or Hip
Phase of Trial: Phase III
Latest Information Update: 29 Mar 2018
At a glance
- Drugs Fasinumab (Primary) ; Celecoxib; Diclofenac
- Indications Pain
- Focus Registrational; Therapeutic Use
- Acronyms FACT OA2
- Sponsors Regeneron Pharmaceuticals
- 12 Mar 2018 Planned End Date changed from 5 Jun 2020 to 15 Jun 2020.
- 12 Mar 2018 Planned primary completion date changed from 6 Jul 2019 to 15 Jul 2019.
- 04 Dec 2017 Status changed from not yet recruiting to recruiting.